Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer. — PRO-LAPSII

Prevention of Venous Thromboembolism Clinical Trial

Official title:
Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer: a Randomized, Double Blind, Placebo-controlled Study.

Status Completed

Clinical Trial Summary

Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer: a randomized, double blind, placebo-controlled study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Prevention of Venous Thromboembolism
Thromboembolism
Venous Thromboembolism

Clinical Trial Details

NCT number	NCT03055026
Study type	Interventional
Source	Fadoi Foundation, Italy
Contact
Status	Completed
Phase	Phase 3
Start date	May 3, 2017
Completion date	September 6, 2021

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06193863` - An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure
Completed	`NCT04267718` - Efficacy of the Use of Risk Scores in Reducing Important Clinical Outcomes in Hospitalized Medical Ill Patients	N/A
Completed	`NCT01184989` - Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate	Phase 4
Recruiting	`NCT01072747` - Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass	Phase 3
Recruiting	`NCT01072955` - Efficacy And Safety Of Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass	Phase 3